IGM Biosciences Inc (IGMS)
8.33
-0.38
(-4.36%)
USD |
NASDAQ |
May 31, 16:00
8.31
-0.02
(-0.24%)
After-Hours: 20:00
IGM Biosciences SG&A Expense (Annual): 50.07M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 50.07M |
| December 31, 2022 | 49.74M |
| December 31, 2021 | 38.30M |
| December 31, 2020 | 18.25M |
| Date | Value |
|---|---|
| December 31, 2019 | 9.241M |
| December 31, 2018 | 3.829M |
| December 31, 2017 | 2.508M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
9.241M
Minimum
2019
50.07M
Maximum
2023
33.12M
Average
38.30M
Median
2021
SG&A Expense (Annual) Benchmarks
| Oragenics Inc | 5.452M |
| Rezolute Inc | 12.18M |
| GT Biopharma Inc | 7.11M |
| 180 Life Sciences Corp | 10.69M |
| Sensei Biotherapeutics Inc | 18.76M |